Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(11):1619–1623. doi: 10.1054/bjoc.2001.2127

Rituximab: mechanisms and applications

P W M Johnson 1,1, M J Glennie 2
PMCID: PMC2363990  PMID: 11742477

Full Text

The Full Text of this article is available as a PDF (58.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alas S., Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001 Jul 1;61(13):5137–5144. [PubMed] [Google Scholar]
  2. Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001 Mar;7(3):709–723. [PubMed] [Google Scholar]
  3. Bubien J. K., Zhou L. J., Bell P. D., Frizzell R. A., Tedder T. F. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993 Jun;121(5):1121–1132. doi: 10.1083/jcb.121.5.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Byrd J. C., Murphy T., Howard R. S., Lucas M. S., Goodrich A., Park K., Pearson M., Waselenko J. K., Ling G., Grever M. R. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001 Apr 15;19(8):2153–2164. doi: 10.1200/JCO.2001.19.8.2153. [DOI] [PubMed] [Google Scholar]
  5. Casey P. J. Protein lipidation in cell signaling. Science. 1995 Apr 14;268(5208):221–225. doi: 10.1126/science.7716512. [DOI] [PubMed] [Google Scholar]
  6. Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–446. doi: 10.1038/74704. [DOI] [PubMed] [Google Scholar]
  7. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J. V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652–656. doi: 10.1073/pnas.95.2.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V., Deconinck E., Haïoun C., Foussard C., Sebban C. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001 Jan 1;97(1):101–106. doi: 10.1182/blood.v97.1.101. [DOI] [PubMed] [Google Scholar]
  9. Cragg M. S., French R. R., Glennie M. J. Signaling antibodies in cancer therapy. Curr Opin Immunol. 1999 Oct;11(5):541–547. doi: 10.1016/s0952-7915(99)00010-2. [DOI] [PubMed] [Google Scholar]
  10. Czuczman M. S., Grillo-López A. J., McLaughlin P., White C. A., Saleh M., Gordon L., LoBuglio A. F., Rosenberg J., Alkuzweny B., Maloney D. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol. 2001 Jan;12(1):109–114. doi: 10.1023/a:1008395214584. [DOI] [PubMed] [Google Scholar]
  11. Czuczman M. S., Grillo-López A. J., White C. A., Saleh M., Gordon L., LoBuglio A. F., Jonas C., Klippenstein D., Dallaire B., Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999 Jan;17(1):268–276. doi: 10.1200/JCO.1999.17.1.268. [DOI] [PubMed] [Google Scholar]
  12. Davis T. A., Grillo-López A. J., White C. A., McLaughlin P., Czuczman M. S., Link B. K., Maloney D. G., Weaver R. L., Rosenberg J., Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000 Sep;18(17):3135–3143. doi: 10.1200/JCO.2000.18.17.3135. [DOI] [PubMed] [Google Scholar]
  13. Deans J. P., Kalt L., Ledbetter J. A., Schieven G. L., Bolen J. B., Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem. 1995 Sep 22;270(38):22632–22638. doi: 10.1074/jbc.270.38.22632. [DOI] [PubMed] [Google Scholar]
  14. Deans J. P., Robbins S. M., Polyak M. J., Savage J. A. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem. 1998 Jan 2;273(1):344–348. doi: 10.1074/jbc.273.1.344. [DOI] [PubMed] [Google Scholar]
  15. Einfeld D. A., Brown J. P., Valentine M. A., Clark E. A., Ledbetter J. A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988 Mar;7(3):711–717. doi: 10.1002/j.1460-2075.1988.tb02867.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Foran J. M., Cunningham D., Coiffier B., Solal-Celigny P., Reyes F., Ghielmini M., Johnson P. W., Gisselbrecht C., Bradburn M., Matthews J. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11 (Suppl 1):117–121. [PubMed] [Google Scholar]
  17. Foran J. M., Gupta R. K., Cunningham D., Popescu R. A., Goldstone A. H., Sweetenham J. W., Pettengell R., Johnson P. W., Bessell E., Hancock B. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol. 2000 Apr;109(1):81–88. doi: 10.1046/j.1365-2141.2000.01965.x. [DOI] [PubMed] [Google Scholar]
  18. Foran J. M., Rohatiner A. Z., Cunningham D., Popescu R. A., Solal-Celigny P., Ghielmini M., Coiffier B., Johnson P. W., Gisselbrecht C., Reyes F. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000 Jan;18(2):317–324. doi: 10.1200/JCO.2000.18.2.317. [DOI] [PubMed] [Google Scholar]
  19. Ghetie M. A., Bright H., Vitetta E. S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001 Mar 1;97(5):1392–1398. doi: 10.1182/blood.v97.5.1392. [DOI] [PubMed] [Google Scholar]
  20. Golay J. T., Clark E. A., Beverley P. C. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985 Dec;135(6):3795–3801. [PubMed] [Google Scholar]
  21. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G. M., Bernasconi S., Tedesco F., Rambaldi A., Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000 Jun 15;95(12):3900–3908. [PubMed] [Google Scholar]
  22. Hainsworth J. D., Burris H. A., 3rd, Morrissey L. H., Litchy S., Scullin D. C., Jr, Bearden J. D., 3rd, Richards P., Greco F. A. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000 May 15;95(10):3052–3056. [PubMed] [Google Scholar]
  23. Harjunpä A., Junnikkala S., Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000 Jun;51(6):634–641. doi: 10.1046/j.1365-3083.2000.00745.x. [DOI] [PubMed] [Google Scholar]
  24. Hoffman M., Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol. 2000 Jun;109(4):900–901. doi: 10.1046/j.1365-2141.2000.109004900.x. [DOI] [PubMed] [Google Scholar]
  25. Johnson P. W., Swinbank K., MacLennan S., Colomer D., Debuire B., Diss T., Gabert J., Gupta R. K., Haynes A., Kneba M. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Ann Oncol. 1999 Nov;10(11):1349–1354. doi: 10.1023/a:1008385924543. [DOI] [PubMed] [Google Scholar]
  26. Kansas G. S., Tedder T. F. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol. 1991 Dec 15;147(12):4094–4102. [PubMed] [Google Scholar]
  27. Kanzaki M., Shibata H., Mogami H., Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem. 1995 Jun 2;270(22):13099–13104. doi: 10.1074/jbc.270.22.13099. [DOI] [PubMed] [Google Scholar]
  28. Kuehnle I., Huls M. H., Liu Z., Semmelmann M., Krance R. A., Brenner M. K., Rooney C. M., Heslop H. E. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15;95(4):1502–1505. [PubMed] [Google Scholar]
  29. Magni M., Di Nicola M., Devizzi L., Matteucci P., Lombardi F., Gandola L., Ravagnani F., Giardini R., Dastoli G., Tarella C. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000 Aug 1;96(3):864–869. [PubMed] [Google Scholar]
  30. Mathas S., Rickers A., Bommert K., Dörken B., Mapara M. Y. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 2000 Dec 15;60(24):7170–7176. [PubMed] [Google Scholar]
  31. McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825–2833. doi: 10.1200/JCO.1998.16.8.2825. [DOI] [PubMed] [Google Scholar]
  32. Milpied N., Vasseur B., Parquet N., Garnier J. L., Antoine C., Quartier P., Carret A. S., Bouscary D., Faye A., Bourbigot B. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11 (Suppl 1):113–116. [PubMed] [Google Scholar]
  33. O'Brien S. M., Kantarjian H., Thomas D. A., Giles F. J., Freireich E. J., Cortes J., Lerner S., Keating M. J. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15;19(8):2165–2170. doi: 10.1200/JCO.2001.19.8.2165. [DOI] [PubMed] [Google Scholar]
  34. O'Keefe T. L., Williams G. T., Davies S. L., Neuberger M. S. Mice carrying a CD20 gene disruption. Immunogenetics. 1998 Jul;48(2):125–132. doi: 10.1007/s002510050412. [DOI] [PubMed] [Google Scholar]
  35. Polyak M. J., Tailor S. H., Deans J. P. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol. 1998 Oct 1;161(7):3242–3248. [PubMed] [Google Scholar]
  36. Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Zarling J., Kidd P., Thomas E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987 Feb;69(2):584–591. [PubMed] [Google Scholar]
  37. Saleh M. N., Gutheil J., Moore M., Bunch P. W., Butler J., Kunkel L., Grillo-López A. J., LoBuglio A. F. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000 Dec;27(6 Suppl 12):99–103. [PubMed] [Google Scholar]
  38. Shan D., Ledbetter J. A., Press O. W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998 Mar 1;91(5):1644–1652. [PubMed] [Google Scholar]
  39. Smeland E., Godal T., Ruud E., Beiske K., Funderud S., Clark E. A., Pfeifer-Ohlsson S., Ohlsson R. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6255–6259. doi: 10.1073/pnas.82.18.6255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Stashenko P., Nadler L. M., Hardy R., Schlossman S. F. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980 Oct;125(4):1678–1685. [PubMed] [Google Scholar]
  41. Szöllósi J., Horejsí V., Bene L., Angelisová P., Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol. 1996 Oct 1;157(7):2939–2946. [PubMed] [Google Scholar]
  42. Tedder T. F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994 Sep;15(9):450–454. doi: 10.1016/0167-5699(94)90276-3. [DOI] [PubMed] [Google Scholar]
  43. Tedder T. F., Schlossman S. F. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem. 1988 Jul 15;263(20):10009–10015. [PubMed] [Google Scholar]
  44. Vitetta E. S., Uhr J. W. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res. 1994 Oct 15;54(20):5301–5309. [PubMed] [Google Scholar]
  45. Vose J. M., Link B. K., Grossbard M. L., Czuczman M., Grillo-Lopez A., Gilman P., Lowe A., Kunkel L. A., Fisher R. I. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001 Jan 15;19(2):389–397. doi: 10.1200/JCO.2001.19.2.389. [DOI] [PubMed] [Google Scholar]
  46. Voso M. T., Pantel G., Weis M., Schmidt P., Martin S., Moos M., Ho A. D., Haas R., Hohaus S. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol. 2000 Jun;109(4):729–735. doi: 10.1046/j.1365-2141.2000.02084.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES